All In Biotech

Investigational drug · Phase 2

SPL84

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cystic Fibrosis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "SPL84"

First trial start

2024

Jun 24, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SPL84", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cystic Fibrosis

Approved drugs for the same conditions: Cystic fibrosis · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "SPL84" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Cystic Fibrosis

  • VX-121D-IVA, CTP-656Phase 33 trials

    Vertex Pharmaceuticals · Cystic Fibrosis

  • ARCT-032Phase 21 trial

    Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation

  • CMTX-101Phase 21 trial

    Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis

  • ETD001Phase 21 trial

    Enterprise Therapeutics Ltd · Cystic Fibrosis

  • RCT2100Phase 21 trial

    ReCode Therapeutics · Cystic Fibrosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.